{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.6","value":"71.5"},{"groupId":"OG001","spread":"1.7","value":"69.4"}]}],"title":"Prior to cycle 1 (baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.1","value":"73.2"},{"groupId":"OG001","spread":"2.1","value":"69.8"}]}],"title":"Prior to cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.2","value":"71.5"},{"groupId":"OG001","spread":"2.2","value":"64.6"}]}],"title":"Prior to cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.2","value":"71.6"},{"groupId":"OG001","spread":"2.1","value":"70.2"}]}],"title":"6 months post cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.2","value":"71.8"},{"groupId":"OG001","spread":"2.2","value":"70.7"}]}],"title":"12 months post cycle 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"298"},{"groupId":"OG001","value":"302"}],"units":"Participants"}],"description":"Patient reported physical functioning was measured with physical functioning subscale of the RAND SF-36. The Physical Functioning Subscale consists of 10 items concerning activities of daily living: walking, climbing stairs, bathing, dressing, and performance of physical activities. Each item is rated on a three-point scale of limitation of activity due to the patients' health from 1=limited a lot to 3=not limited. The total PF score is the summation of item scores and then rescaled to 0-100. A larger score suggests better physical functioning.","dispersionType":"Standard Error","groups":[{"description":"All patients who received paclitaxel and carboplatin chemotherapy and were included in the chemotherapy analysis","id":"OG000","title":"Paclitaxel and Carboplatin Chemotherapy"},{"description":"All patients who received paclitaxel and carboplatin chemotherapy with bevacizumab followed by bevacizumab maintenance therapy and were included in the chemotherapy analysis","id":"OG001","title":"Paclitaxel and Carboplatin Chemotherapy With Bevacizumab"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Provided baseline and at least one follow-up assessments (data were combined and analyzed according to randomized chemotherapy regimen, regardless of surgical assignment, as pre-specified in the study protocol).","reportingStatus":"POSTED","timeFrame":"1. Prior to cycle 1 (baseline), 2. Prior to cycle 3 (6 weeks post cycle 1), 3. Prior to cycle 6 (15 weeks post cycle 1), 4. 6 months post cycle 1, 5. 12 months post cycle 1.","title":"Patient Reported Physical Function (Chemotherapy Analysis)","type":"SECONDARY","unitOfMeasure":"score on a scale"}